Neladalkib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Neladalkib
- Molecular weight
- 452.92
- Structure (SMILES)
- CCn1nc(Cl)c2c1-c1cnc(N)c(c1)O[C@H](C)c1cc(F)ccc1-c1nn(C)cc1C2
- 4 8 metheno 8h dipyrazolo 3 4 h 4 3 k 2 5 benzoxaazacyclotetradecin 7 amine 1 chloro 3 ethyl 12 fluoro 3 10 16 18 tetrahydro 10 16 dimethyl 10r
- 4,8-Metheno-8H-dipyrazolo[3,4-h:4′,3′-k][2,5]benzoxaazacyclotetradecin-7-amine, 1-chloro-3-ethyl-12-fluoro-3,10,16,18-tetrahydro-10,16-dimethyl-, (10R)-
- neladalkib
- Neladalkib
- Neladalkib (NVL-655)
- Neladalkib [INN]
- Neladalkib [USAN]
- Neladalkib [WHO-DD]
- neladalkib inn
- neladalkib nvl 655
- neladalkib usan
- neladalkib who dd
- nuv 655
- NUV-655
- nvl 655
- NVL-655
- CAS registry numbers
- 2739866-40-9
- ChEMBL ID
- CHEMBL6068023
- InChIKey
- FWZSCAQEBTVTOM-GFCCVEGCSA-N
- PubChem compound IDs
- 164718816
- FDA ingredient codes (UNII)
- J32P26A6BC
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- neladalkib
- Type
- Synthetic organic
- Drug name stem
- -alkib
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ALK receptor tyrosine kinase
- Gene symbol
- ALK
- Protein identifier
- Q9UM73
- Median affinity
- 9
- Affinity units
- pIC50
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 83.78
- Calculated partition coefficient (ALogP)
- 4.78
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 32
- Molecular formula
- C23H22ClFN6O
- Monoisotopic mass
- 452.1527652
- Natural product
- No
Related records
Trials (3)
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
In development for (1)
- Neoplasm Phase 2